C91.A

Clinical Causes: Genetic mutations: Specific chromosomal translocations involving the MYC gene, such as t(8;14), are commonly associated. Infections: Epstein-Barr Virus (EBV) infection has been linked to the development of Burkitt-type leukemias, particularly in endemic regions. Immunodeficiency: Conditions like HIV/AIDS or other immunosuppressive states can increase susceptibility. Environmental factors: Exposure to certain chemicals or radiation may contribute, though evidence is limited. Family history: A familial predisposition to lymphoid cancers can play a role, although it is rare.

Key Symptoms: Rapidly enlarging lymph nodes, often in the abdomen, neck, or other areas. B symptoms, including fever, night sweats, and unintentional weight loss. Bone pain or tenderness, especially if the leukemia infiltrates the marrow extensively. Fatigue and weakness due to anemia. Bleeding or easy bruising resultant from low platelet counts. Gastrointestinal symptoms like nausea, vomiting, or abdominal distension if the abdomen is involved. Elevated lactate dehydrogenase (LDH) levels, indicating high cell turnover.

Diagnosis Path: Diagnosing mature B-cell leukemia, Burkitt-type, involves a combination of clinical evaluation and laboratory investigations. Key diagnostic steps include: - Blood Tests: Complete blood count (CBC) to assess blood cell levels, which often show anemia, thrombocytopenia, or leukocytosis. - Bone Marrow Biopsy: Evaluates marrow infiltration by malignant cells. - Imaging: CT or PET scans to detect lymph node and organ involvement. - Lymph node or tissue biopsy: Confirms diagnosis histologically and immunohistochemically. - Cytogenetic analysis: Detects characteristic chromosomal translocations involving the MYC gene. - Lumbar puncture: May be performed to evaluate central nervous system involvement. Early diagnosis relies on recognizing symptoms and confirming through these investigative procedures.

Treatment Protocols: Managing mature B-cell leukemia, Burkitt-type, typically involves intensive combination therapy. Treatment options include: - Chemotherapy: Regimens like CODOX-M/IVAC are commonly used, tailored to the patient's age and overall health. - Targeted therapy: Emerging treatments targeting specific genetic or molecular features. - Supportive care: Blood transfusions, infection control, and management of side effects. - Central nervous system prophylaxis: Intrathecal chemotherapy to prevent CNS involvement. - Stem cell transplantation: Considered in relapsed or refractory cases. Given the aggressive nature of this leukemia, treatment often requires hospitalization and close monitoring. Multidisciplinary care teams are essential for optimal management.